echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: Androgen-affected signals weaken the therapeutic effect of dositas on the aggressive resistance to prostate cancer.

    Br J Cancer: Androgen-affected signals weaken the therapeutic effect of dositas on the aggressive resistance to prostate cancer.

    • Last Update: 2020-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Androgen-affected (AR) signaling pathlands drive tumor growth in prostate cancer and treat drug resistance.
    advanced or metastatic prostate cancer (PCa) is mainly focused on androgen deprivation therapy (ADT).
    although ADT generally causes the disease to subside, most prostate cancers become resistant due to changes in the androgen-borne (AR) signaling pathline.
    cancer, also known as hyperly resistant prostate cancer (CRPC), is still progressing after the initial acceptance of ADT.
    docetaxel is a standard first-line chemotherapy drug, and recent clinical studies have showed that the combination of docetaxel and ADT can be effective in improving the prognostic prognostics of hormone-sensitive diseases.
    testosterone supplementation can seriously impair the accumulation and efficacy of dorcamine The study aims to explore whether testosterone and AR signals interfere with the efficacy of dorcestion in the treatment of CRPC.
    researchers found that in the CRPC model, testosterone supplementation significantly affected the accumulation of dossythase in tumors, thereby reducing the stability of micro-tube proteins and anti-tumor effects.
    testosterone and AR signal activity interfere with the anti-tumor effects of dossythase, testosterone can compete with dossythase for the intake of the drug transporter protein OATP1B3.
    regardless of the stability of the micro-tube protein caused by Dorsey, testosterone-induced AR signaling paths can counteract the therapeutic effect of Dorsey.
    the activation of ar signaling paths can also reverse the long-term tumor receding effects caused by dossytherapy.
    results suggest that to optimize the therapeutic effect of dossythase, it is necessary to inhibit androgen levels and the activity of the AR signal transducting path.
    , the study revealed that in hyperactive prostate cancer, the continued activity of androgen-like signals maximizes the inhibition of the effects of targeted therapy drugs in combined therapy with dositase.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.